An Open Study of Foscarnet Treatment First Episode CMV-Retinitis in AIDS Patients

Sponsor
Astra USA (Industry)
Overall Status
Completed
CT.gov ID
NCT00002039
Collaborator
(none)
1

Study Details

Study Description

Brief Summary

To evaluate the safety and efficacy of foscarnet induction therapy for treatment of AIDS patients experiencing their first episode of cytomegalovirus (CMV) retinitis. To evaluate the safety and efficacy of three different foscarnet maintenance therapy regimens. To determine the pharmacokinetics of intermittent administration of foscarnet with or without concomitant administration of zidovudine (AZT).

Condition or Disease Intervention/Treatment Phase
  • Drug: Foscarnet sodium
N/A

Study Design

Study Type:
Interventional
Primary Purpose:
Treatment
Official Title:
An Open Study of Foscarnet Treatment First Episode CMV-Retinitis in AIDS Patients

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Exclusion Criteria

    Co-existing Condition:
    Patients with the following are excluded:
    • Any clinically significant pulmonary or neurologic impairment (e.g., patients who are intubated or comatose).

    • Corneal, lens, or vitreous opacification which precludes examination of the fundi, or evidence of tuberculotic, diabetic and/or hypertensive retinopathy.

    • Known allergy to foscarnet.

    • Recurrent episode of cytomegalovirus (CMV) retinitis.

    Concurrent Medication:
    Excluded:
    • Nephrotoxic drugs.
    Patients with the following are excluded:
    • Recurrent episode of cytomegalovirus (CMV) retinitis.

    • Any clinically significant pulmonary or neurologic impairment (e.g., patients who are intubated or comatose).

    • Corneal, lens, or vitreous opacification which precludes examination of the fundi, or evidence of tuberculotic, diabetic, and/or hypertensive retinopathy.

    • Known allergy to foscarnet.

    Prior Medication:
    Excluded:
    • Ganciclovir for cytomegalovirus (CMV) retinitis.

    • Foscarnet for CMV retinitis.

    Patients with AIDS as defined by the CDC with manifest first episode cytomegalovirus (CMV) retinitis, as identified by its characteristic ophthalmoscopic appearance and verified by fundus photography.

    • Patients must be able to give informed consent.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Foscarnet Research Program / Park Plaza Hosp Houston Texas United States 77004

    Sponsors and Collaborators

    • Astra USA

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00002039
    Other Study ID Numbers:
    • 020A
    • 88-FOS-01
    First Posted:
    Aug 31, 2001
    Last Update Posted:
    Jun 24, 2005
    Last Verified:
    Mar 1, 1991

    Study Results

    No Results Posted as of Jun 24, 2005